Orquidea Tablet
Product Images NDC 70700-316

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Orquidea (NDC 70700-316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (D995e0c0 9fa7 440f 8646 C54c3967fc7c 01)

Chemical structure of norethindrone, the active ingredient in Orquidea oral tablets by Xiromed, LLC. The structure shows a steroid framework with hydroxyl and acetylene functional groups.*

FDA Label Image

Figure 1 (D995e0c0 9fa7 440f 8646 C54c3967fc7c 02)

A pharmacokinetic curve showing plasma concentration (Cpo) over time up to 48 hours for an oral 0.35 mg dose of the medication. The graph illustrates peak levels shortly after administration and declines over time, approaching baseline near 48 hours.*

FDA Label Image

3s Carton (Image 01)

Packaging label for Orquidea™ norethindrone tablets, USP 0.35 mg oral tablets by Xiromed, LLC. The label indicates 3 pouches, each containing one blister pack of 28 tablets. The packaging includes the product name, strength, route, NDC 70700-316-85, and the labeler Xiromed, LLC. It also states this product is an oral contraceptive and Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.